The startup develops an antibiotic-free treatment that utilizes natural substances to restore vaginal pH levels and inhibit biofilm formation, providing a safe and effective alternative for managing bacterial and fungal infections. This approach offers women a solution that avoids the side effects associated with traditional antibiotic therapies.
Funding
$6.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Bacterial vaginosis (BV) is a common recurring vaginal infection that causes discomfort and stress for women worldwide. Current treatments often involve antibiotics, which can lead to antibiotic resistance, negatively impact the vaginal microbiome, and result in secondary fungal infections and high recurrence rates.
Solution
Gedea Biotech offers _p_Hyph, an antibiotic-free vaginal tablet designed to treat and prevent bacterial vaginosis by restoring a healthy vaginal environment. The tablet's formulation lowers the vaginal pH to a normal level, dissolves existing biofilms, prevents biofilm formation, and promotes the growth of beneficial lactobacilli. _p_Hyph's active ingredient, GDL, is a well-documented and safe substance already approved as a food additive. Clinical studies have demonstrated that _p_Hyph provides rapid symptom relief, a high cure rate, and a significantly lower recurrence rate compared to antibiotic treatments, without causing secondary fungal infections or contributing to antimicrobial resistance.
Target Audience
The primary target audience includes women experiencing bacterial vaginosis and healthcare providers seeking effective, antibiotic-free treatment options.
Features
- Antibiotic-free formulation to avoid antimicrobial resistance
- Contains GDL (Glucono-delta-lactone), a safe and well-documented active ingredient
- Lowers vaginal pH to inhibit the growth of harmful bacteria
- Dissolves and prevents the formation of biofilms
- Promotes the growth of beneficial lactobacilli to restore a healthy vaginal microbiome
- Demonstrated rapid symptom relief, with many patients experiencing relief from odor within one day
- Significantly lower recurrence rate compared to antibiotic treatments in clinical studies
- Does not cause secondary fungal infections